Focus on Heart Health

Patients with ASCVD and a history of MI are at especially high risk for repeat adverse cardiac events. Listen in as Dr. Bill Boden summarizes a post hoc analysis of such patients from the REDUCE-IT trial. Can icosapent ethyl plus a statin provide improved carioprotection by reducing recurrent events in this population? Tune in to learn more!

REDUCE-IT is a landmark trial that examined the coadministration of icosapent ethyl and statins in patients for secondary and primary prevention of recurrent events and demonstrated a significant reduction in the key primary and secondary endpoints. This discussion relates to a post hoc analysis of a subset of patients who had prior myocardial infarction, as part of the REDUCE-IT study, and comprised about 45% of the patients with established atherosclerotic coronary disease. The results of this post-MI analysis bring into clear focus that treating hypertriglyceridemia is a critical variable in terms of reducing dyslipidemic risk and overall risk.

Since the 2017 AHA/ACC/HFSA guidelines, considerable research has been conducted in the care of patients with heart failure, including the impact of iron deficiency. The new 2022 guidelines have considerable updates based on the totality of current evidence. Join Dr. Adrian Hernandez and Dr. Marco Metra as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.

The 2022 updates to the ACC/AHA guidelines for heart failure are the first since 2017. In the interim, considerable research has been conducted on the impact of optimal RAASi therapy and the management of hyperkalemia in patients with heart failure. Join Dr. Mikhail Kosiborod and Dr. Michael Böhm as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.

When compared to the options available to coronary artery disease patients, advances in treatment for peripheral artery disease have unfortunately been lacking. But now that’s all changing with the introduction of drug-eluting stents as a treatment option, as explained by the President of Lankenau Heart Institute at Main Line Health Dr. William Gray.

This innovative, 30-minute, CME activity features 5 leading experts addressing complex issues when treating patients with residual cardiovascular disease (CVD) risk, using triglyceride-rich lipoprotein (TGRL) science and management. The program is based on a live satellite symposium (held during the time of AHA-2018), where REDUCE-IT results were 1st presented after a late-breaking clinical trial presentation. Challenges faced by healthcare providers in caring for patients with elevated TGRL are addressed. Topics include:

• Central Role of Triglyceride-rich Lipoproteins (TGRL) in CVD Residual Risk beyond Statin Therapy
• Biologic Basis for TGRL Modulation in Reducing Atherosclerosis
• Clinical Evidence on Reducing TGRL-based Residual Risk: REDUCE-IT

For more information, contact Medtelligence, LLC at [email protected].

Thanks to recent advancements in technology, physicians are now able to transition from a reactive approach to heart failure treatment to a proactive one. Providing insight into this pivot and the essential devices that are making this switch possible is Dr. Devi Nair, an electrophysiologist at St. Bernards Heart and Vascular.

Based on a live symposium held on April 26, 2018, this innovative, 15-minute, case-based CME activity features two prominent faculty covering important, timely clinical issues and recent data related to anticoagulation in patients after percutaneous coronary interventions.

This CME activity is based on a live symposium held on April 26, 2018. It features a 15-minute Video Expert Dialogue with two internationally renowned faculty evaluating clinical issues and recent data regarding anticoagulation in patients with coronary artery disease (CAD).

Following a successful ventricular assist device clinical trial, Dr. Jennifer Caudle is joined by Dr. Eduardo Rame, Cardiologist at the Hospital of the University of Pennsylvania, to discuss how this innovative technology is improving survival rates and decreasing the risk of adverse effects, such as stroke, gastrointestinal bleeding, and infection, in heart failure patients.

Dr. Brian McDonough is joined by Dr. Mark Zucker, Director of the Cardiothoracic Transplantation Program at RWJBH/Newark Beth Israel Medical Center, and his HCM patient and founder of the Hypertrophic Cardiomyopathy Association, Lisa Salberg, to discuss her inspiring story and the importance of early diagnosis.